Spots Global Cancer Trial Database for celgene
Every month we try and update this database with for celgene cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | NCT00424047 | Multiple Myelom... | CC-5013 plus de... Dexamethasone p... | 18 Years - | Celgene | |
| Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | NCT00126893 | Myeloid Leukemi... | CC-401 | 18 Years - | Celgene | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes | NCT00064974 | Myelodysplastic... | CC-5013 | 18 Years - | Celgene | |
| Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00072722 | Prostate Cancer | CC-4047 | 18 Years - | Celgene | |
| Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | NCT01074047 | Acute Myeloid L... | Azacitidine Conventional Ca... | 65 Years - | Celgene | |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | NCT01201811 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | NCT00478777 | Relapsed or Ref... | Lenalidomide dexamethasone | 18 Years - | Celgene | |
| Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer | NCT02027428 | Squamous Cell C... | Abraxane (Induc... Carboplatin (In... Abraxane (Maint... Best Supportive... Abraxane (Induc... Carboplatin (In... Best Supportive... | 18 Years - | Celgene | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer | NCT00179699 | Non-Small Cell ... | CC-5013 pemetrexed | 18 Years - | Celgene | |
| Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) | NCT00179660 | Non-Hodgkins Ly... | Lenalidomide | 18 Years - | Celgene | |
| A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes | NCT00458159 | Myelodysplastic... | CC-11006 | 18 Years - | Celgene | |
| Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179712 | Ovarian Cancer | CC-5013 topotecan | 18 Years - | Celgene Corporation | |
| Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | NCT00072722 | Prostate Cancer | CC-4047 | 18 Years - | Celgene | |
| A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | NCT00405756 | Newly Diagnosed... | Lenalidomide: D... Melphalan Prednisone Aspirin Placebo Lenalidomide: D... Lenalidomide: O... | 65 Years - | Celgene Corporation | |
| Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality | NCT00065156 | Myelodysplastic... | lenalidomide | 18 Years - | Celgene | |
| Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | NCT00179673 | Non-Hodgkins Ly... | Lenalidomide | 18 Years - | Celgene | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT00474188 | Diffuse Large B... | CC-5013 (lenali... dexamethasone | 18 Years - | Celgene | |
| Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality | NCT00179621 | Myelodysplastic... | Lenalidomide 5 ... Lenalidomide 10... Placebo | 18 Years - | Celgene | |
| A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes | NCT00458159 | Myelodysplastic... | CC-11006 | 18 Years - | Celgene | |
| Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer | NCT00179699 | Non-Small Cell ... | CC-5013 pemetrexed | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
